Please login to the form below

Not currently logged in
Email:
Password:

Warp Drive Bio names Gregory Verdine as CEO

Joined by James Nichols as chief operating officer and new board member Julian Adams

Warp Drive Bio Gregory Verdine Genomics firm Warp Drive Bio has named its co-founder Gregory Verdine as CEO.

He replaces founding CEO Alexis Brosy who is set to become executive chairman of the Cambridge, US-based company.

In addition to this succession, Warp Drive Bio announced that Dr James Nichols will join the company as chief operating officer and Dr Julian Adams will join the board of directors.

The reorganisation is part of Warp Drive Bio's plans to advance its programmes of genomic technologies to discover natural-source drugs, as part of which it has a £125m partnership with Sanofi.

“Today, this is underscored by the appointment of three proven, renowned and tenacious drug discovery and development experts to our team,” said departing CEO Borisy.

His replacement Dr Verdine helped launch the company in 2012 after an entrepreneurial career that included co-founding several biotech companies, including Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Aileron Therapeutics, Tokai Pharmaceuticals, Ontorii Pharmaceuticals and Eleven Biotherapeutics.

He has also served as a global consultant for Roche, scientific adviser to Vertex and Ariad, and currently sits on the boards of the US National Cancer Institute and the SMA Foundation.

“The research being conducted by the Warp Drive Bio team is one of the most exciting scientific enterprises that I have ever been a part of, and I am thrilled to lead the company as we enter our next phase of growth and progress,” he said.

Dr Nichols joins as chief operating officer from Resolvyx Pharmaceuticals, where he was president and chief operating officer.

Dr Adams is president of R&D at Infinity Pharmaceuticals having served at Millennium Pharmaceuticals, where he had global responsibility for multiple drug discovery programmes, including the successful discovery and development of cancer treatment Velcade (bortezomib).

4th July 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics